Fig. 1From: A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancerOverall survival (a) and cancer specific survival (b) in patients treated with degarelix and patients in whom degarelix was switched to gonadotropin releasing hormone agonistBack to article page